MustGrow Biologics Corp. Announces Results of Shareholder Meeting
Saskatoon, Saskatchewan--(Newsfile Corp. - June 26, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce the results of its 2025 annual meeting of shareholders (the "Meeting") held on June 26, 2025. At the Meeting, all...
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2025-06-26 6:15 PM EDT | MustGrow Biologics Corp.
Hemostemix Announces Lead Order of $1,500,000 and the Full Repayment of $2,500,000 Convertible Debenture
Calgary, Alberta--(Newsfile Corp. - June 26, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces its Chairman, Peter Lacey, has provided the Company with a lead order for a non brokered private placement in the amount of $1,500,000 for Units at...
Biotechnology, Pharmaceuticals, Health
2025-06-26 9:00 AM EDT | Hemostemix Inc.
New CPT Codes for Totally Implantable Active Middle Ear Hearing Implants Go into Effect July 1, Unlocking New Opportunities for Envoy Medical
White Bear Lake, Minnesota--(Newsfile Corp. - June 26, 2025) - Envoy Medical, Inc. (NASDAQ: COCH), a revolutionary hearing health company focused on fully implanted hearing devices that leverage the ear's natural anatomy, today announced that five Category III CPT codes for totally implantable...
Biotechnology, Healthcare and Hospitals
2025-06-26 8:00 AM EDT | Envoy Medical, Inc.
Medexus Announces Strong Fiscal Year 2025 Results, Including Initial Results from Launch of GRAFAPEX (treosulfan) for Injection in the United States
Fiscal year 2025 revenue of $108.3 million, record net income of $2.2 million, operating income of $8.2 million, and record Adjusted EBITDA* of $20.2 million US commercial launch of GRAFAPEX™ executed in February 2025, following swiftly on the FDA's approval in January 2025, with initial...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-06-25 6:15 PM EDT | Medexus Pharmaceuticals Inc.
InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced...
Biotechnology, Pharmaceuticals
2025-06-25 8:00 AM EDT | InMed Pharmaceuticals
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort
Marlborough, Massachusetts--(Newsfile Corp. - June 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that the Safety...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-06-25 7:45 AM EDT | Phio Pharmaceuticals Corp.
PreveCeutical Announces Date for Annual General and Special Meeting
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has scheduled its annual general and special meeting for August 15, 2025, at which the shareholders...
Biotechnology, Pharmaceuticals, Health
2025-06-25 7:00 AM EDT | PreveCeutical Medical Inc.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Marlborough, Massachusetts--(Newsfile Corp. - June 24, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-06-24 7:45 AM EDT | Phio Pharmaceuticals Corp.
InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study
Vancouver, British Columbia--(Newsfile Corp. - June 24, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or t
Biotechnology, Pharmaceuticals
2025-06-24 7:00 AM EDT | InMed Pharmaceuticals
PlasCred Circular Innovations Inc. Announces Extension of Strategic Private Placement Closing
Calgary, Alberta--(Newsfile Corp. - June 23, 2025) - PlasCred Circular Innovations Inc. (CSE: PLAS) (FSE: XV2) ("PlasCred" or the "Company"), a transformative leader in the advanced plastic waste recycling sector, is pleased to announce that it has extended the closing of its previously announced...
Technology, Biotechnology, Bioplastics
2025-06-23 8:55 AM EDT | PlasCred Circular Innovations Inc.
IR-MED Reports Positive Interim Results from U.S. Clinical Study of PressureSafe(TM) for Pressure Injury Assessment Across Diverse Skin Tones
PressureSafe™, IR-MED's lead product, demonstrated 94% sensitivity in assessing tissue at risk for pressure injuries prior to visible skin breakdown Technology addresses longstanding disparities in skin assessment, particularly in patients with darker skin tones Results presented at HCA...
Technology, Biotechnology, Healthcare and Hospitals, Health
2025-06-23 8:30 AM EDT | IR-MED, Inc.
Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer
Philadelphia, Pennsylvania--(Newsfile Corp. - June 23, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the appointment of Andrew Smith as Chief Operating Officer. Andrew joins Medicus with over three decades of experience and is an accomplished...
Banking / Financial Services, Biotechnology, Investment Banking, Health
2025-06-23 7:30 AM EDT | Medicus Pharma Ltd.